Reversing bone loss by directing mesenchymal stem cells to bone

Stem Cells

Volumn 31, Issue 9, 2013, Pages 2003-2014

  Yao, Wei ^a   Guan, Min ^a   Jia, Junjing ^a   Dai, Weiwei ^a   Lay, Yu An E ^a   Amugongo, Sarah ^a   Liu, Ruiwu ^a   Olivos, David ^a   Saunders, Mary ^a,b   Lam, Kit S ^a   Nolta, Jan ^b   Olvera, Diana ^c   Ritchie, Robert O ^c   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California Berkeley   (United States)

Author keywords

Bone marrow stromal cells; Cell migration; In vivo tracking; Integrins; Stem cell transplantation

Indexed keywords

ALENDRONIC ACID; HYDROXYAPATITE; PEPTIDOMIMETIC AGENT; PROTEIN KINASE B; PROTEIN LLP2A; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE STRENGTH; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; CORTICAL BONE; ENZYME PHOSPHORYLATION; ESTROGEN DEFICIENCY; EXTRACELLULAR MATRIX; FEMALE; IN VITRO STUDY; LYMPHOCYTE TRANSFORMATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; TRABECULAR BONE;

BONE MARROW STROMAL CELLS; CELL MIGRATION; IN VIVO TRACKING; INTEGRINS; STEM CELL TRANSPLANTATION;

AGING; ALENDRONATE; ANIMALS; BONE AND BONES; BONE RESORPTION; CELL DIFFERENTIATION; CELL MOVEMENT; DIPEPTIDES; ESTROGENS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOGENESIS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PHOSPHOTYROSINE; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84885090951     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1461     Document Type: Article

References (63)

1. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353: 555-565.
2. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-588.
3. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
4. Sethe S, Scutt A, Stolzing A,. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5: 91-116.
5. Brack AS, Rando TA,. Intrinsic changes and extrinsic influences of myogenic stem cell function during aging. Stem Cell Rev 2007; 3: 226-237.
6. Muschler GF, Nitto H, Boehm CA, et al. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001; 19: 117-125.
7. Zhang Y, Luo H, Zhang Z, et al. A nerve graft constructed with xenogeneic acellular nerve matrix and autologous adipose-derived mesenchymal stem cells. Biomaterials 2010; 31: 5312-5324.
8. Schuleri KH, Feigenbaum GS, Centola M, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 2009; 30: 2722-2732.
9. Pedram MS, Dehghan MM, Soleimani M, et al. Transplantation of a combination of autologous neural differentiated and undifferentiated mesenchymal stem cells into injured spinal cord of rats. Spinal Cord 2010; 48: 457-463.
10. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON Randomized Trial. JAMA 2012; 308: 2369-2379.
11. Gutwald R, Haberstroh J, Kuschnierz J, et al. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: Comparison with augmentation by autologous bone in adult sheep. Br J Oral Maxillofac Surg 2010; 48: 285-290.
12. Vertenten G, Lippens E, Girones J, et al. Evaluation of an injectable, photopolymerizable, and three-dimensional scaffold based on methacrylate- endcapped poly(D,L-lactide-co-epsilon-caprolactone) combined with autologous mesenchymal stem cells in a goat tibial unicortical defect model. Tissue Eng Part A 2009; 15: 1501-1511.
13. Longobardi L, Granero-Molto F, O'Rear L, et al. Subcellular localization of IRS-1 in IGF-I-mediated chondrogenic proliferation, differentiation and hypertrophy of bone marrow mesenchymal stem cells. Growth Factors 2009; 27: 309-320.
14. Chapel A, Bertho JM, Bensidhoum M, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003; 5: 1028-1038.
15. Granero-Molto F, Weis JA, Miga MI, et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 2009; 27: 1887-1898.
16. Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169: 12-20.
17. Meyerrose TE, De Ugarte DA, Hofling AA, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 2007; 25: 220-227.
18. Cho SW, Sun HJ, Yang JY, et al. Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol Ther 2009; 17: 1979-1987.
19. Peng L, Liu R, Marik J, et al. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2006; 2: 381-389.
20. Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012; 18: 456-462.
21. Herberg S, Hill WD,. Two birds with one bone? IBMS BoneKEy 2012; 9: 1.
22. Yao W, Dai W, Shahnazari M, et al. Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice. Plos One 2010; 5: e11410.
23. Yao W, Cheng Z, Shahnazari M, et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 2010; 25: 190-199.
24. Yao W, Cheng Z, Pham A, et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008; 58: 3485-3497.
25. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28: 2-17.
26. Turner CH, Burr DB,. Basic biomechanical measurements of bone: A tutorial. Bone 1993; 14: 595-608.
27. Chen XD, Dusevich V, Feng JQ, et al. Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J Bone Miner Res 2007; 22: 1943-1956.
28. Zhu H, Mitsuhashi N, Klein A, et al. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Stem Cells 2006; 24: 928-935.
29. Lin H, Yang G, Tan J, et al. Influence of decellularized matrix derived from human mesenchymal stem cells on their proliferation, migration and multi-lineage differentiation potential. Biomaterials 2012; 33: 4480-4489.
30. Lee SH, Lee YJ, Han HJ,. Role of hypoxia-induced fibronectin-integrin beta1 expression in embryonic stem cell proliferation and migration: Involvement of PI3K/Akt and FAK. J Cell Physiol 2011; 226: 484-493.
31. Lee DH, Park BJ, Lee MS, et al. Chemotactic migration of human mesenchymal stem cells and MC3T3-E1 osteoblast-like cells induced by COS-7 cell line expressing rhBMP-7. Tissue Eng 2006; 12: 1577-1586.
32. Zhang Q, Liu G, Wu Y, et al. BDNF promotes EGF-induced proliferation and migration of human fetal neural stem/progenitor cells via the PI3K/Akt pathway. Molecules 2011; 16: 10146-10156.
33. Veevers-Lowe J, Ball SG, Shuttleworth A, et al. Mesenchymal stem cell migration is regulated by fibronectin through alpha5beta1-integrin-mediated activation of PDGFR-beta and potentiation of growth factor signals. J Cell Sci 2011; 124: 1288-1300.
34. Ryu CH, Park SA, Kim SM, et al. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem Biophys Res Commun 2010; 398: 105-110.
35. Huveneers S, Truong H, Fassler R, et al. Binding of soluble fibronectin to integrin alpha5 beta1-link to focal adhesion redistribution and contractile shape. J Cell Sci 2008; 121: 2452-2462.
36. Discher DE, Janmey P, Wang YL,. Tissue cells feel and respond to the stiffness of their substrate. Science 2005; 310: 1139-1143.
37. Engler AJ, Sen S, Sweeney HL, et al. Matrix elasticity directs stem cell lineage specification. Cell 2006; 126: 677-689.
38. Zeiger AS, Loe FC, Li R, et al. Macromolecular crowding directs extracellular matrix organization and mesenchymal stem cell behavior. Plos One 2012; 7: e37904.
39. Cieslik M, Mertas A, Morawska-Chochol A, et al. The evaluation of the possibilities of using PLGA co-polymer and its composites with carbon fibers or hydroxyapatite in the bone tissue regeneration process-in vitro and in vivo examinations. Int J Mol Sci 2009; 10: 3224-3234.
40. Fu J, Wang YK, Yang MT, et al. Mechanical regulation of cell function with geometrically modulated elastomeric substrates. Nat Methods 2010; 7: 733-736.
41. Ip JE, Wu Y, Huang J, et al. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 2007; 18: 2873-2882.
42. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201.
43. Fierro F, Illmer T, Jing D, et al. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 2007; 40: 355-366.
44. Mukherjee A, Rotwein P,. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci 2009; 122: 716-726.
45. Weinstein RS, Jilka RL, Almeida M, et al. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 2010; 151: 2641-2649.
46. Selman C, Tullet JM, Wieser D, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326: 140-144.
47. Ruvinsky I, Meyuhas O,. Ribosomal protein S6 phosphorylation: From protein synthesis to cell size. Trends Biochem Sci 2006; 31: 342-348.
48. Sato M, Vahle J, Schmidt A, et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 2002; 143: 3230-3242.
49. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010; 25: 2647-2656.
50. Nauta AJ, Fibbe WE,. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
51. Fibbe WE, Nauta AJ, Roelofs H,. Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci 2007; 1106: 272-278.
52. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150.
53. Yanez R, Lamana ML, Garcia-Castro J, et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582-2591.
54. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-2767.
55. Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010; 25: 2412-2418.
56. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-1745.
57. Byeon YE, Ryu HH, Park SS, et al. Paracrine effect of canine allogenic umbilical cord blood-derived mesenchymal stromal cells mixed with beta-tricalcium phosphate on bone regeneration in ectopic implantations. Cytotherapy 2010; 12: 626-636.
58. Dao MA, Pepper KA, Nolta JA,. Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model. Stem Cells 1997; 15: 443-454.
59. Horwitz EM, Prather WR,. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: Expanding the spectrum of cell therapy. Isr Med Assoc J 2009; 11: 209-211.
60. Wu X, Pang L, Lei W, et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010; 7: 571-580.
61. Tang Y, Wu X, Lei W, et al. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757-765.
62. Weitzmann MN, Cenci S, Rifas L, et al. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000; 96: 1873-1878.
63. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755.